G6PC1 and type 2 diabetes mellitus: In T2D patients, high-glucose treatment upregulated FTO mRNA expression, resulting in a decrease in m6A, further inducing mRNA expression of metabolic genes such as Glucose-6-Phosphatase Catalytic Subunit 1 (G6PC), and Diacylglycerol O-Acyltransferase 2 (DGAT2) [338].